Skip to main content

Health condition · Clinically reviewed

Ganglioglioma, a rare glial-neuronal tumour with a very treatable core.

Most often WHO grade 1 and cortical-based, ganglioglioma is a leading cause of drug-resistant temporal lobe epilepsy in young people. Surgery is usually curative.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a UK clinician familiar with neuro-oncology and epilepsy surgery before publication.

  • 02

    Sourced from guidance

    Checked against WHO 2021 CNS tumour classification, NICE, RCPath and specialist paediatric and adult neuro-oncology standards.

  • 03

    Current for 2026

    Reflects modern UK practice including BRAF V600E testing, targeted therapy, and NHS specialist commissioned epilepsy surgery pathways.

Key facts

Ganglioglioma at a glance.

The essentials, in plain English. What it is, where it sits, and how it is treated by specialist commissioned services in the UK.

  • What it is

    A rare mixed glial-neuronal brain tumour made of both dysplastic neurons and neoplastic glial cells. WHO 2021 grade 1 in the majority, with rare grade 3 anaplastic variants.

  • How common

    Around 1 per cent of all brain tumours, but up to 40 per cent of brain tumours associated with epilepsy in children and young adults.

  • Who it affects

    Peak presentation in the second and third decades of life. Children and young adults dominate, though adult diagnosis is well described.

  • Where it sits

    Most often in the temporal lobe, particularly the mesial temporal region. Strong link with drug-resistant focal epilepsy.

  • Molecular signature

    A BRAF V600E mutation is found in roughly half of cases and is directly targetable with BRAF and MEK inhibitors.

  • Mainstay of care

    Surgical resection led by a specialist commissioned neuro-oncology and epilepsy surgery MDT. Complete resection is curative in most.

Why this guide matters

A rare tumour with a clear pathway.

Ganglioglioma sits at the intersection of neuro-oncology and epilepsy surgery. Understanding both is the fastest route to seizure freedom and durable tumour control.

  • Surgery is the mainstay

    Gross total resection by a specialist commissioned team is curative in the majority of WHO grade 1 ganglioglioma.

  • Epilepsy surgery matters

    When seizures are drug-resistant, resection is planned through an epilepsy surgery MDT and often stops the seizures entirely.

  • BRAF V600E opens targeted therapy

    Around half of cases carry a BRAF V600E mutation, which is directly treatable with BRAF and MEK inhibitors when needed.

How the diagnosis is made

From first seizure to a specialist plan.

The steps a UK neuro-oncology and epilepsy surgery team will normally follow, in order, so you know what to expect and why.

  1. 01

    Assessing

    Clinical assessment and seizure history

    A structured neurological history focusing on focal impaired awareness seizures, aura, and any drug-resistance to antiseizure medication.

  2. 02

    Assessing

    MRI brain with contrast

    The key imaging test. Ganglioglioma is typically well-circumscribed, cortical-based, T1 hypointense, T2 hyperintense, often with calcification, a cystic component and rim enhancement.

  3. 03

    Assessing

    Epilepsy protocol and PET selectively

    A dedicated epilepsy MRI protocol, sometimes with FDG-PET, helps distinguish ganglioglioma from focal cortical dysplasia and other epileptogenic lesions.

  4. 04

    Confirming

    Neuro-oncology MDT review

    A specialist commissioned paediatric or adult neuro-oncology MDT reviews imaging alongside epilepsy surgery colleagues before any biopsy or resection.

  5. 05

    Confirming

    Surgical biopsy and neuropathology

    Tissue is examined by specialist neuropathology with immunohistochemistry for neuronal and glial markers, plus BRAF V600E testing to confirm the diagnosis.

  6. 06

    Preparing

    Molecular profiling

    BRAF V600E status and wider molecular profiling guide the WHO 2021 grade and open the door to targeted therapy where appropriate.

  7. 07

    Preparing

    Epilepsy surgery workup

    When drug-resistant epilepsy is present, video EEG telemetry and neuropsychology feed into the epilepsy surgery MDT plan.

Typical timeline: from first MRI to specialist MDT plan in weeks, with surgery scheduled by a specialist commissioned centre.

Symptoms

What ganglioglioma actually looks like.

Most people present with focal seizures. Read on for the classic temporal lobe patterns, other neurological features and the red flags that mean it is time to escalate. See our guide to epilepsy.

  • Focal impaired awareness seizures

    Classic temporal lobe seizures with aura, altered awareness, automatisms and post-ictal confusion. See our guide to epilepsy for more.

  • Drug-resistant focal epilepsy

    Seizures that do not settle on two well-chosen antiseizure medications trigger a formal epilepsy surgery pathway.

  • Aura and déjà vu

    Rising epigastric sensation, déjà vu, fear and olfactory aura are typical mesial temporal features.

  • Headache

    Not universal, but persistent or new-pattern headache, especially with focal signs, warrants imaging.

  • Focal neurological signs

    Variable, depending on tumour location. Speech, memory or subtle motor changes are possible with temporal or extra-temporal lesions.

  • Cognitive and memory change

    Subtle memory or word-finding difficulty can accompany mesial temporal disease and is picked up on neuropsychology testing.

  • Incidental finding

    A small number are found on scans done for other reasons. Even then, specialist neuro-oncology review is essential.

  • Red flag - new focal deficit

    A new focal neurological deficit, new severe headache with vomiting, or first-ever seizure needs urgent assessment.

Treatment

How ganglioglioma is treated in the UK.

Surgery first, planned through a specialist commissioned neuro-oncology and, where relevant, epilepsy surgery clinic MDT. Targeted therapy through the BRAF and MEK inhibitor clinic is available for BRAF V600E-mutant disease that cannot be resected.

  • Surgical resection

    The mainstay of care. Gross total resection by a specialist commissioned neurosurgery team is curative in the majority of grade 1 ganglioglioma.

  • Epilepsy surgery pathway

    Where drug-resistant epilepsy is present, resection is planned through an epilepsy surgery MDT. See our guide to the epilepsy surgery clinic.

  • Adjuvant radiotherapy

    Selective use for atypical or anaplastic grade 3 ganglioglioma, subtotal resection or recurrence. Delivered by specialist neuro-oncology.

  • Stereotactic radiosurgery

    Gamma Knife or CyberKnife can be considered for small residual or recurrent lesions in carefully selected cases.

  • BRAF and MEK inhibitors

    Dabrafenib with trametinib is the targeted option for BRAF V600E-mutant unresectable or recurrent disease. Specialist commissioned only.

  • Chemotherapy

    A limited, selective role for progressive or high-grade disease, often when surgery and radiotherapy are not enough.

  • Antiseizure medication

    Continued alongside every other treatment. Choice and duration are tailored by a specialist epilepsy service, even after successful surgery.

  • Neuropsychology and rehabilitation

    Post-operative support with neuropsychology, speech therapy and, where needed, rehabilitation helps recovery and long-term function.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, WHO CNS tumour classification, and specialist commissioned service standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Ganglioglioma is a specialist commissioned condition. Decisions are made by your neuro-oncology and epilepsy surgery teams alongside you and your family.

  • WHO Classification of Tumours of the Central Nervous System, 5th edition (2021).

  • NICE. Brain tumours (primary) and brain metastases in adults (NG99).

  • Royal College of Pathologists. Dataset for tumours of the central nervous system.

  • NHS England. Specialised commissioning service specifications for neurosciences and neuro-oncology.

  • International League Against Epilepsy (ILAE). Recommendations on epilepsy surgery in lesional focal epilepsy.

Red flags

When ganglioglioma needs urgent attention.

Most day-to-day care is planned through routine specialist follow-up. These are the situations where earlier or urgent contact is warranted.

  • First-ever seizure

    Any first seizure in a child, young person or adult needs urgent same-week assessment and, in most cases, brain imaging.

  • Drug-resistant focal epilepsy

    Ongoing seizures despite two appropriate antiseizure medications should prompt referral to a specialist epilepsy surgery service.

  • New focal neurological deficit

    New weakness, speech disturbance, visual field loss or persistent unilateral symptoms warrant urgent neuro-oncology assessment.

  • New severe or progressive headache

    Especially with vomiting, morning worsening, or focal signs. Consider raised intracranial pressure and image urgently.

  • Rapid clinical change

    Rapid change in seizure pattern, cognition or behaviour in a known ganglioglioma patient may signal transformation or progression.

  • Post-operative deterioration

    New deficit, seizures or severe headache after surgery needs same-day contact with the neurosurgery team.

  • Concerning imaging change

    New enhancement, growth or oedema on follow-up MRI is discussed at the neuro-oncology MDT before treatment changes.

  • Psychological distress

    A brain tumour diagnosis is a major life event. Low mood, anxiety and family stress deserve early support.

  • Genetic and family concerns

    Rare familial patterns warrant clinical genetics input, especially in young patients with multiple lesions.

Living with it

A rare tumour, with a clear pathway.

Four things that make the biggest difference over time. A specialist MDT, active seizure care, planned MRI follow-up, and support from trusted charities.

A quiet reminder

Consistency beats intensity, every time.

Small, steady habits kept up for years, alongside expert follow-up, do more than any short burst of effort.

  1. 01 Team

    Stay under a specialist MDT

    Ganglioglioma is a specialist commissioned condition. Regular follow-up with neuro-oncology and, where relevant, epilepsy surgery is essential.

  2. 02 Seizures

    Keep seizure care active

    Antiseizure medication continues after surgery in most people. Any change in seizure pattern is a reason to contact the epilepsy team.

  3. 03 Scans

    Follow-up MRI is routine, not scary

    Long-term surveillance MRI is the norm. Most scans are reassuring and help catch any change early.

  4. 04 Support

    Use trusted charities

    The Brain Tumour Charity and Children with Cancer UK offer practical, financial and emotional support alongside specialist care.

Frequently asked

Everything we get asked about ganglioglioma.

Quick answers on grade, seizures, surgery, BRAF V600E and long-term outlook.

  • What is a ganglioglioma?

    Ganglioglioma is a rare mixed glial-neuronal brain tumour containing both dysplastic neurons and neoplastic glial cells. Most are WHO 2021 grade 1, slow-growing lesions, though rare anaplastic grade 3 forms exist. It accounts for around 1 per cent of all brain tumours but up to 40 per cent of brain tumours associated with epilepsy in children and young adults.

  • How does ganglioglioma usually present?

    Most people present with seizures, classically focal impaired awareness seizures arising from the temporal lobe. Many go on to develop drug-resistant focal epilepsy. Some present with headache, focal neurological signs or as an incidental MRI finding. See our guide to epilepsy for more on seizure types.

  • How is ganglioglioma diagnosed?

    MRI brain is the key test. A ganglioglioma is typically a well-circumscribed, cortical-based lesion, T1 hypointense and T2 hyperintense, often with calcification, a cystic component and rim enhancement. Definitive diagnosis needs specialist neuropathology of a surgical sample, with immunohistochemistry and BRAF V600E testing.

  • What is the main treatment?

    Surgery is the mainstay. A gross total resection performed by a specialist commissioned neurosurgery team is curative in most grade 1 ganglioglioma. When drug-resistant epilepsy is present, resection is planned through an epilepsy surgery MDT and can also stop or greatly reduce seizures.

  • What is BRAF V600E and why does it matter?

    BRAF V600E is a mutation in the BRAF gene found in around half of ganglioglioma cases. It is directly targetable with BRAF inhibitors such as dabrafenib combined with MEK inhibitors such as trametinib. This offers a specialist commissioned treatment option for unresectable or recurrent BRAF V600E-mutant disease. See our guide to the BRAF and MEK inhibitor clinic.

  • What is the long-term outlook?

    For WHO grade 1 ganglioglioma treated with complete surgical resection, long-term outcomes are very good, with many people achieving lasting seizure control and durable tumour control. Regular MRI follow-up, ongoing epilepsy care and specialist neuro-oncology review are part of standard long-term care.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.